Forecasted · Cooperative Agreement
Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents
National Institutes of Health, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents
- Issuing agency
- National Institutes of Health (Department of Health and Human Services)
- Opportunity number
- PAR-26-049
- Funding type
- Cooperative Agreement
- Funding purpose
- Health
- Status
- Forecasted
- Application deadline
- Forecasted · estimated close February 13, 2026 (agency estimate)
- Agency estimates
- Estimated posting: December 13, 2025. Estimated award date: December 1, 2026. Estimates can change.
- Published award range
- Not published by the agency
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see Additional Information on Eligibility)
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.242
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/360576 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 360576 · Funding opportunity number PAR-26-049
- Posted
- September 12, 2025 · Source last updated September 12, 2025
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 92% of key fields published by the sourceNot published: published funding range.
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Eligibility details (from the agency)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Description (from the official listing)
The National Institute of Mental Health (NIMH) seeks research that helps determine the best dosing strategies when testing new psychiatric medications in children and adolescents with serious mental illnesses.This NOFO will focus on developing and refining central nervous system (CNS) tools and models that can show how medications affect the brain in young people. These tools might include functional brain imaging methods like EEG or fMRI, as well as digital health measures or cognitive assessments. Studies are encouraged that explore how dosing impacts drug exposure (pharmacokinetics) and related CNS functional effects (pharmacodynamics). The overall goal is to improve the safety and effectiveness of pediatric clinical trials by developing pediatric pharmacodynamic measures, to associate pharmacodynamic data with pharmacokinetic data, and to establish associated models. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Researchers with expertise in pediatric psychiatry, neuroimaging, pediatric clinical pharmacology, clinical trials, or related fields are encouraged to consider applying to the new NOFO.
Agency contact
Margaret C. Grabb, Ph.D.
mgrabb@mail.nih.gov